EN DE

STRATA Skin Sciences, Inc (SSKN) Fair Value & Analysis

Healthcare · US · Market cap $707K

SS STRATA Skin Sciences, Inc logo STRATA Skin Sciences, Inc SSKN · US
Price$0.0055
Fair Value$0.0054
Upside-1.8%
Quality32/100
Watch STRATA Skin Sciences, Inc for free, get notified when fair value or trend changes. Watch for free
Mixed Growth
Loss-making · -20.4% net margin
High debt · negative free cash flow
Trails peers (4/11)
Narrow moat 9/100
Evidence: Low Range $0.0049 – $0.0054 Share as image

Fair value as of: Jul 29, 2026

From 1 valuation models · updated 12 days ago

Share price −94.5% over the past month.

Below-average quality, currently priced close to our fair value.

What matters now

  • The price sits close to our fair value, market and models broadly agree here, little valuation tension.
  • The models converge in a tight band ($0.0049 to $0.0054), unusually little disagreement for a valuation.
  • Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

$19.30 $0.0004 Fair Value $0.0054 Apr 2021 Jul 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 29, 2026.

How to read this chart

60‑month range $0.0004 – $19.30 · fair‑value band $0.0049 – $0.0054 · the $0.0055 price screens above the $0.0054 fair value. Dashed = 300-day average. As of Jul 29, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

STRATA Skin Sciences, Inc (SSKN) currently trades at $0.0055, while our model-based Fair Value estimate is $0.0054, implying the stock looks roughly 1.8% fairly valued today. The Quality Score stands at 32/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).

Over the trailing twelve months, STRATA Skin Sciences, Inc generated revenue of $30.7M at a net margin of -20.4%. Revenue declined 3.0% year over year. Net debt stands at $8.4M. Fundamentals as of Jul 29, 2026

Our scenario range runs from $0.0049 (bear case) to $0.0054 (bull case); at $0.0055, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. For context, the median of 10 Healthcare peers we cover trades at -22% fair-value upside, at -2%, SSKN screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
NCAV (Graham) $0.0100 $0.0200 $0.0200 50
All 1 models by family
Asset-Based
NCAV (Graham) $0.0100 $0.0200 $0.0200 50

Notify me when SSKN reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) $30.7M
Revenue growth (YoY) -3.0%
Net margin -20.4%
Return on equity -159%
Free cash flow −$4.3M FY2025
Operating margin 0.4%
More key figures
EPS (TTM) $-1.35
Net debt $8.4M FY2025

Figures from reported company fundamentals · as of Jul 29, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 32/100

Of which business quality 31 · Market factors (momentum, volatility) 19

Profitability 35
Margins and returns on capital today
Quality Growth 69
Are margins and returns improving?
Cashflow 0
Earnings quality: real cash, not paper profit
Fin. Strength 22
Balance sheet, leverage, solvency risk
Investment 95
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 10
Price trend over the last 3–12 months (market factor)
52W Momentum 0
Distance to the 52-week high (market factor)
Net Issuance 0
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

STRATA Skin Sciences, Inc., a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, China, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America.

Full company description

STRATA Skin Sciences, Inc., a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, China, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. It operates through Dermatology Recurring Procedures and Dermatology Procedures Equipment segments. The company offers XTRAC excimer laser and VTRAC lamp systems, which are used in the treatment of psoriasis, vitiligo, atopic dermatitis, and leukoderma; and TheraClear acne therapy system for the treatment of mild to moderate inflammatory, comedonal, and pustular acne. It serves dermatologists and dermatological group clinics. The company was formerly known as MELA Sciences, Inc. and changed its name to STRATA Skin Sciences, Inc. in December 2015. STRATA Skin Sciences, Inc. was incorporated in 1989 and is headquartered in Horsham, Pennsylvania.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

STRATA Skin Sciences, Inc reported revenue of $30.7M in FY2025 versus $30.0M in FY2021, a compound +0.6%/yr. Reported net income was −$6.3M in FY2025.

Growth Quality 10/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Latest Revenue (FY 2025)
$30.7M
Latest YoY
−8.5%
Avg. growth/yr (3Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
−5.3%
Avg. growth/yr (5Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+5.9%
Avg. growth/yr (25Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+22.1%
Revenue +0.6%/yr
FY21 $30.0M
FY22 $36.2M
FY23 $33.4M
FY24 $33.6M
FY25 $30.7M
Net income
FY21 −$2.7M
FY22 −$5.5M
FY23 −$10.8M
FY24 −$10.1M
FY25 −$6.3M

Watch SSKN: get an alert when its fair value changes →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "STRATA Skin Sciences, Inc Fair Value". https://www.fairvalue-calculator.com/stock/SSKN

Peer Group

Medical Devices · 352 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 31 · Bottom 25%
Fair Value upside −2% · Above median
Return on assets -11% · Bottom 25%
Net margin (TTM) -20% · Bottom 25%
Operating margin (TTM) 0% · Below median
Revenue growth -3% · Below median
Debt / equity 5.22× · Higher than 75% of peers

Valuation Multiples vs Medical Devices median · lower = cheaper

P/B 0.24× · Cheaper than 75% of peers
P/S (TTM) 0.02× · Cheaper than 75% of peers
PEG 0.03× · Cheaper than 75% of peers

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 31 · sector 0
FUTURE 0 · sector 29
PAST 0 · sector 8
HEALTH 0 · sector 97
DIVIDEND 0 · sector 38

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 29, 2026).

Stock Price Fair Value vs Fair Value
Abbott Laboratories, ABT $100.68 $74.79 -26%
Stryker Corporation SYK $316.44 $186.28 -41%
Medtronic plc MDT $83.56 $65.57 -22%
Boston Scientific Corporation BSX $43.04 $38.44 -11%
Edwards Lifesciences Corporation EW $85.73 $41.02 -52%
Siemens Healthineers AG SHL €34.59 €33.87 -2%
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥149.43 ¥147.63 -1%
Shanghai United Imaging Healthcare Co 688271 ¥109.00 ¥43.60 -60%
Demant A/S DEMANT kr 276.60 kr 161.17 -42%
Getinge AB GETIB kr 206.80 kr 192.14 -7%

Compare STRATA Skin Sciences, Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is STRATA Skin Sciences, Inc (SSKN) overvalued or undervalued?
As of Jul 29, 2026, our model estimates a fair value of $0.0054 versus a price of $0.0055, about −2% (fairly valued).
What is the fair value of SSKN?
Our model-based fair value for STRATA Skin Sciences, Inc is $0.0054 (as of Jul 29, 2026), built from audited fundamentals. The current price is $0.0055.
What is the quality score of SSKN?
STRATA Skin Sciences, Inc has a Quality Score of 32/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of STRATA Skin Sciences, Inc (SSKN)?
STRATA Skin Sciences, Inc reported trailing-twelve-month revenue of about $30.7M (latest available figure, as of Jul 29, 2026).
What is the net profit margin of SSKN?
The net profit margin of STRATA Skin Sciences, Inc is about -20.4%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track STRATA Skin Sciences, Inc and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.